C. Vargas

Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile

A. Soza, C. Vargas, M. Espinoza, 2015, PloS one.

Medication review with follow-up for cardiovascular outcomes: a trial based cost-utility analysis.

V. García-Cárdenas, S. Benrimoj, Francisco Martínez-Mardones, 2021, Journal of comparative effectiveness research.

Costs and consequences of chronic pain due to musculoskeletal disorders from a health system perspective in Chile

C. Vargas, M. Espinoza, C. Balmaceda, 2018, Pain reports.

Cost utility of a pharmacist-led minor ailment service compared with usual pharmacist care

Kylie A. Williams, V. García-Cárdenas, S. Benrimoj, 2020, Cost Effectiveness and Resource Allocation.

Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison

C. Vargas, M. Espinoza, A. Giglio, 2019, Expert review of pharmacoeconomics & outcomes research.

Cost-utility analysis of medication review with follow-up for cardiovascular outcomes: A microsimulation model.

S. Benrimoj, V. García-Cárdenas, Francisco Martínez-Mardones, 2021, Health policy.